01 Rising Prevalence of Merkel Cell Carcinoma The rising incidence of MCC worldwide, particularly in developed regions like North America and Europe, is a prominent aspect driving the growth of the MCC therapies market. The American Cancer Society reported that approximately 2,000 instances of MCC are identified annually in the United States, with the occurrence rate steadily increasing in recent decades. Likewise, a research paper published in PubMed revealed that from 2000 to 2013, there was a significant 95% rise in the number of reported instances of MCC, in contrast to a 57% increase for melanoma and a 15% increase for all other types of 'solid' malignancies. The incidence rate of Merkel cell carcinoma (MCC) in the United States was 0.7 per 100,000 person-years in 2013, resulting in 2,488 cases.Moreover, the incidence of MCC exhibited an exponential growth pattern with advancing age, ranging from 0.1 to 1.0 to 9.8 (per 100,000 person-years) in the age categories of 40–44, 60–64, and 85+ years, respectively. As a result of the increasing age of the "baby-boom" generation, it is projected that the incidence of US MCC will rise to 2,835 cases in 2020 and 3,284 cases in 2025. Hence, the increasing incidence of MCC, in conjunction with the aging demographic, is propelling the growth of the global market.
02 Growing Research and Development Another factor contributing to the growth of the MCC therapeutics market is the progress made in developing innovative therapeutics for MCC. For instance, in October 2022, Tempus, a precision medicine company, announced its collaboration with Kartos Therapeutics to create a companion diagnostic (CDx) for the ongoing Phase II clinical trial of navtemadlin (KRT-232). This CDx aims to identify patients with TP53 wild-type (TP53WT) Merkel cell carcinoma (MCC) who are suitable for treatment with the drug candidate.In May 2023, Phio Pharmaceuticals obtained approval from the US Food and Drug Administration (FDA) to begin a clinical trial of PH-762, an investigational new drug (IND) for treating skin carcinomas. PH-762, an INTASYL chemical, decreases the expression of cell death Protein 1 (PD-1), which hampers the ability of T lymphocytes to eliminate cancer cells. The company plans to initiate the Phase Ib clinical trial of intratumoral PH-762 in patients with cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma later this year.
01 Lack of Diagnosis Or Misdiagnosis A significant limitation of the MCC therapeutics market is the absence of accurate or incorrect MCC diagnoses, resulting in delayed or inadequate treatment and unfavorable prognosis. Due to its same visual characteristics and symptoms, MCC is frequently misidentified as other cutaneous diseases, including basal cell carcinoma, melanoma, squamous cell carcinoma, or cysts.Diagnosing MCC can be challenging because of its rarity and the need for specific testing, such as immunohistochemistry, electron microscopy, or polymerase chain reaction (PCR), to definitively detect the existence of MCPyV or MCV. Consequently, a significant number of people suffering from MCC are accurately diagnosed once the disease has reached an advanced stage. This diminishes the likelihood of survival and amplifies the expenses and complexity of treatment.
01 Development of Personalized Medicine and Biomarkers The advancement of personalized medicine and biomarkers for MCC enhances the ability to diagnose, predict the outcome, and treat MCC, hence offering opportunities for global market expansion. Personalized medicine is a medical practice or approach that customizes treatment depending on the characteristics of each patient, including their genetic composition, molecular profile, and reaction to medication.Biomarkers are biological markers that may be quantified within the body, including genes, proteins, or metabolites. They offer insights into a disease's existence, intensity, or advancement, as well as the efficacy or harmfulness of a treatment. By combining personalized medicine with biomarkers, MCC can find the patients most benefit from immunotherapy and then carefully track their progress and side effects. PD-L1 expression on tumor cells or the tumor microenvironment can be a biomarker for predicting the response to avelumab or other PD-L1 inhibitors. Likewise, the amount of MCPyV or MCV present in the blood or tissue can function as a biomarker for tracking the progression and reappearance of the disease.
January 2026 Merck & Co. continued expanding its immuno-oncology research initiatives involvingKEYTRUDA® (pembrolizumab) across multiple cancer indications, including rare skin cancers. The company continued evaluating checkpoint inhibitor-based approaches to improve treatment options for patients with advanced cancers.
November 2025 Regeneron Pharmaceuticals expanded oncology development activities involving Libtayo® (cemiplimab-rwlc), an anti-PD-1 therapy approved for advanced cutaneous cancers, including Merkel cell carcinoma. The company continued advancing immunotherapy-focused treatment strategies for difficult-to-treat skin cancers.
September 2025 EMD Serono and Pfizer continued advancing their immuno-oncology portfolio through clinical development activities involving Bavencio® (avelumab), an approved PD-L1 inhibitor used in Merkel cell carcinoma treatment. The companies continued supporting research into immune checkpoint inhibition approaches.
August 2025 BeiGene expanded its global oncology research initiatives involving immune checkpoint inhibitors and targeted cancer therapies. The company continued developing novel oncology treatment approaches that support broader applications in rare and advanced cancers.